LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global cytomegalovirus (CMV) therapeutics market and the market is poised to grow by USD 241.63 million during 2019-2023 at a CAGR of almost 5% during the forecast period. Request Free Sample Pages
Read the 121-page research report with TOC on "Cytomegalovirus (CMV) Therapeutics Market Analysis Report by RoA (Oral, Parenteral, and Others), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023".
The market is driven by the recurring nature of cytomegalovirus disease. Also, the adoption of mandatory screening tests on newborns is anticipated to further boost the growth of the cytomegalovirus therapeutics market.
CMV is prevalent in more than 40% of all adults around the globe. Infections with multiple strains of CMV are known to occur frequently in patients with low immunity and those suffering from sexually transmitted diseases. If CMV is left untreated, then the patient may develop CMV retinitis. Researchers are studying and developing novel therapies and identifying the new potential indications caused by the virus. The recurring nature of CMV is increasing the sales of CMV therapeutics, which will drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Cytomegalovirus (CMV) Therapeutics Market Companies:
AstraZeneca is headquartered in the UK and operates under the business segment: Biopharmaceuticals. The company offers an immune globulin, CytoGam, which is approved for the treatment of CMV.
Bausch Health is headquartered in Canada and offers products through the following business units: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The company offers an implant, Vitrasert, which is approved for the treatment of CMV in patients with AIDS.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is headquartered in Switzerland and operates under two business segments, namely Pharmaceuticals and Diagnostics. The company offers an antiviral medicine, VALCYTE, which is approved for the treatment of CMV retinitis in people who have acquired AIDS.
Gilead Sciences, Inc.
Gilead Sciences, Inc. is headquartered in the US and offers products through its business segment: Pharmaceuticals. The company offers, Vistide, which is an approved drug for the treatment of CMV retinitis in adults with AIDS.
Merck & Co., Inc.
Merck & Co., Inc. is headquartered in the US and offers products through the following business segments: Pharmaceutical, Animal Health, and Other. The company provides a prescription medicine, PREVYMIS, which is approved for the prevention of CMV infection in adults who have undergone allogeneic HSCT.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform
Cytomegalovirus (CMV) Therapeutics RoA Outlook (Revenue, USD Million, 2019 - 2023)
Cytomegalovirus (CMV) Therapeutics Regional Outlook (Revenue, USD Million, 2019 - 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Health Care include:
Peptide Therapeutics Market – Global Peptide Therapeutics Market by RoA (parenteral, oral, and others) and geography (Americas, APAC, and EMEA).
Ophthalmology Therapeutics Market – Global Ophthalmology Therapeutics Market by product (retinal disorder therapeutics, glaucoma therapeutics, dry eye syndrome therapeutics, eye infections and inflammation therapeutics, and other therapeutics) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.